[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

3 clusters · 8 sources · 29 days · First seen · Last updated

Refining multiple myeloma risk criteria and biomarkers

Overview

Researchers are refining how high‑risk multiple myeloma is identified through new biomarkers and revised clinical benchmarks. An Australian study found that high expression of the protein Desmoglein‑2 (DSG2) in 678 newly diagnosed patients predicts markedly shorter survival, suggesting DSG2 could complement existing genomic tests.

In the United States, investigators re‑examined the definition of functional high‑risk disease in the context of modern quadruplet induction regimens and autologous stem‑cell transplantation. A study of 310 patients published in the journal Cancer suggests that disease progression within 36 months after treatment—rather than the historic 18‑month benchmark—better isolates a high-risk subgroup. This group, comprising approximately 16% of patients, faces a median survival of less than two years after relapse. Dr. Gayathri Ravi of the University of Alabama at Birmingham noted that “with modern therapy, relapse within 36 months, versus the previous 18‑month definition, can be considered functional high‑risk.”

To address this subgroup, researchers recommend prioritizing early T‑cell‑redirecting therapies, CAR‑T, bispecific antibodies, and clinical‑trial enrollment.

Additionally, Spanish investigators from CIMAV and the Clínica Universidad de Navarra have utilized single-cell RNA sequencing to identify changes in the bone marrow microenvironment. Their research highlights how endothelial cells and mesenchymal stem cells evolve from the asymptomatic MGUS stage to active multiple myeloma, creating a supportive environment for tumor growth.

Entities

American Cancer Society · CIMAV · Clinica Universidad de Navarra

Timeline

  1. 25 days ago

    [HEALTH] 2 sources
    Multiple myeloma research identifies bone marrow changes and new risk criteria

    New research highlights changes in the bone marrow microenvironment and proposes extending the risk assessment period from 18 to 36 months to better manage multiple myeloma patients.

  2. about 2 months ago

    [HEALTH] 2 sources
    New 36‑Month Benchmark Redefines High‑Risk Multiple Myeloma

    Research on 310 multiple myeloma patients suggests shifting the high‑risk definition from 18 to 36 months of disease progression, urging early use of CAR‑T and similar therapies for those patients.

  3. about 2 months ago

    [HEALTH] 4 sources
    New Biomarker and Revised Risk Criteria Refine Multiple Myeloma Prognosis

    Researchers in Australia and the US identified DSG2 as a survival marker and redefined high‑risk multiple myeloma criteria, guiding earlier targeted therapies.

Sources

formaremedicala.ro · immedicohospitalario.es · knowridge.com · news-medical.net · noticiasdeNavarra.com · onlinemusica.com.br · osul.com.br · retailpharmacymagazine.com.au